Coherus Oncology (CHRS) Enterprise Value (2014 - 2026)

Coherus Oncology has disclosed Enterprise Value across 13 years of filings, most recently posting $111.0 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 172.62% year-over-year to $111.0 million; the TTM figure through Jun 2026 stood at $111.0 million (up 172.62% YoY), while the FY2025 annual figure was -$85011.7, down 100.25% from the prior year.
• Enterprise Value came in at $111.0 million for Q2 2026 at Coherus Oncology, up from $93.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $672.8 million in Q1 2022 to a low of -$152.8 million in Q2 2025.
• Average Enterprise Value over 5 years is $179.8 million, with a median of $102.3 million recorded in 2026.
• Year-over-year, Enterprise Value sank 481.47% in 2025 and soared 715.59% in 2026.
• Over 5 years, Enterprise Value stood at $432.8 million in 2022, then tumbled by 40.87% to $255.9 million in 2023, then tumbled by 86.89% to $33.6 million in 2024, then tumbled by 100.25% to -$85011.7 in 2025, then surged by 130614.39% to $111.0 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $111.0 million in Q2 2026, $93.6 million in Q1 2026, and -$85011.7 in Q4 2025.